OBJECTIVE: A cohort of high dose-rate (HDR) monotherapy patients was analyzed to (i) establish the frequency of non-malignant urethral stricture; (ii) explore the relation between stricture formation with the dose distribution along the length of the urethra, and MRI radiomics features of the prostate gland. METHODS: A retrospective review of treatment records of patients who received 19 Gy single fraction of HDR brachytherapy (BT) was carried out. A matched pair analysis used one control for each stricture case matched with pre-treatment International Prostate Symptom Score (IPSS) score, number of needles used and clinical target volume volume for each stricture case identified.For all data sets, pre-treatment T2 weighted MRI images were used to define regions of interests along the urethra and within the whole prostate gland. MRI textural radiomics features-energy, contrast and homogeneity were selected. Wilcoxon signed-rank test was performed to investigate significant differences in dosimetric parameters and MRI radiomics feature values between cases and controls. RESULTS: From Nov 2010 to July 2017, there were 178 patients treated with HDR BT delivering 19 Gy in a single dose. With a median follow-up of 28.2 months, a total of 5/178 (3%) strictures were identified.10 patients were included in the matched pair analysis. The urethral dosimetric parameters investigated were not statistically different between cases and controls (p > 0.05). With regards to MRI radiomics feature analysis, significant differences were found in contrast and homogeneity between cases and controls (p < 0.05). However, this did not apply to the energy feature (p = 0.28). CONCLUSION: In this matched pair analysis, no association between post-treatment stricture and urethral dosimetry was identified. Our study generated a preliminary clinical hypothesis suggesting that the MRI radiomics features of homogeneity and contrast of the prostate gland can potentially identify patients who develop strictures after HDR BT. Although the sample size is small, this warrants further validation in a larger patient cohort. ADVANCES IN KNOWLEDGE: Urethral stricture has been reported as a specific late effect with prostate HDR brachytherapy. Our study reported a relatively low stricture rate of 3% and no association between post-treatment stricture and urethral dosimetry was identified. MRI radiomics features can potentially identify patients who are more prone to develop strictures.
OBJECTIVE: A cohort of high dose-rate (HDR) monotherapy patients was analyzed to (i) establish the frequency of non-malignant urethral stricture; (ii) explore the relation between stricture formation with the dose distribution along the length of the urethra, and MRI radiomics features of the prostate gland. METHODS: A retrospective review of treatment records of patients who received 19 Gy single fraction of HDR brachytherapy (BT) was carried out. A matched pair analysis used one control for each stricture case matched with pre-treatment International Prostate Symptom Score (IPSS) score, number of needles used and clinical target volume volume for each stricture case identified.For all data sets, pre-treatment T2 weighted MRI images were used to define regions of interests along the urethra and within the whole prostate gland. MRI textural radiomics features-energy, contrast and homogeneity were selected. Wilcoxon signed-rank test was performed to investigate significant differences in dosimetric parameters and MRI radiomics feature values between cases and controls. RESULTS: From Nov 2010 to July 2017, there were 178 patients treated with HDR BT delivering 19 Gy in a single dose. With a median follow-up of 28.2 months, a total of 5/178 (3%) strictures were identified.10 patients were included in the matched pair analysis. The urethral dosimetric parameters investigated were not statistically different between cases and controls (p > 0.05). With regards to MRI radiomics feature analysis, significant differences were found in contrast and homogeneity between cases and controls (p < 0.05). However, this did not apply to the energy feature (p = 0.28). CONCLUSION: In this matched pair analysis, no association between post-treatment stricture and urethral dosimetry was identified. Our study generated a preliminary clinical hypothesis suggesting that the MRI radiomics features of homogeneity and contrast of the prostate gland can potentially identify patients who develop strictures after HDR BT. Although the sample size is small, this warrants further validation in a larger patient cohort. ADVANCES IN KNOWLEDGE: Urethral stricture has been reported as a specific late effect with prostate HDR brachytherapy. Our study reported a relatively low stricture rate of 3% and no association between post-treatment stricture and urethral dosimetry was identified. MRI radiomics features can potentially identify patients who are more prone to develop strictures.
Authors: Radka Stoyanova; Mandeep Takhar; Yohann Tschudi; John C Ford; Gabriel Solórzano; Nicholas Erho; Yoganand Balagurunathan; Sanoj Punnen; Elai Davicioni; Robert J Gillies; Alan Pollack Journal: Transl Cancer Res Date: 2016-08 Impact factor: 1.241
Authors: Maha Saada Jawad; Joshua T Dilworth; Gary S Gustafson; Hong Ye; Michelle Wallace; Alvaro Martinez; Peter Y Chen; Daniel J Krauss Journal: Int J Radiat Oncol Biol Phys Date: 2015-11-10 Impact factor: 7.038
Authors: Mira Keyes; Stacy Miller; Veronika Moravan; Tom Pickles; Michael McKenzie; Howard Pai; Mitchell Liu; Winkle Kwan; Alexander Agranovich; Ingrid Spadinger; Vincent Lapointe; Ross Halperin; W James Morris Journal: Int J Radiat Oncol Biol Phys Date: 2008-12-26 Impact factor: 7.038
Authors: Pedro J Prada; Juan Cardenal; Ana García Blanco; Javier Anchuelo; María Ferri; Gema Fernández; Elisabeth Arrojo; Andrés Vázquez; Maite Pacheco; José Fernández Journal: Radiother Oncol Date: 2016-04-22 Impact factor: 6.280
Authors: Hashim U Ahmed; Ahmed El-Shater Bosaily; Louise C Brown; Rhian Gabe; Richard Kaplan; Mahesh K Parmar; Yolanda Collaco-Moraes; Katie Ward; Richard G Hindley; Alex Freeman; Alex P Kirkham; Robert Oldroyd; Chris Parker; Mark Emberton Journal: Lancet Date: 2017-01-20 Impact factor: 79.321
Authors: Vanessa Panettieri; Tiziana Rancati; Eva Onjukka; Martin A Ebert; David J Joseph; James W Denham; Allison Steigler; Jeremy L Millar Journal: Front Oncol Date: 2020-06-11 Impact factor: 6.244
Authors: Simon K B Spohn; Alisa S Bettermann; Fabian Bamberg; Matthias Benndorf; Michael Mix; Nils H Nicolay; Tobias Fechter; Tobias Hölscher; Radu Grosu; Arturo Chiti; Anca L Grosu; Constantinos Zamboglou Journal: Theranostics Date: 2021-07-06 Impact factor: 11.556